Clinical Cancer Research CR Balducci Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dalbagni, G.
Right arrow Articles by Reuter, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalbagni, G.
Right arrow Articles by Reuter, V.
Clinical Cancer Research Vol. 7, 2797-2801, September 2001
© 2001 American Association for Cancer Research


Regular Articles

Genetic Alterations in TP53 in Recurrent Urothelial Cancer

A Longitudinal Study

Guido Dalbagni1, Zhi-Ping Ren, Harry Herr, Carlos Cordon-Cardo and Victor Reuter

Departments of Urology [G. D., H. H.] and Pathology [Z-P. R., C. C-C., V. R.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Purpose: Because bladder cancer has a recurrence rate that can be as high as 90% at 2 years, we sought to clarify whether these metachronous tumors are polyclonal or monoclonal in origin. We have examined the genetic alterations of the TP53 gene in a cohort of patients with urothelial cancer who underwent multiple biopsies at different times and sites because of tumor recurrence and/or progression. We postulated that if tumor cells at different points in the natural history of the disease contain an identical mutation in the TP53 gene, this pattern could provide evidence for the monoclonality of the recurrent bladder tumors.

Experimental Design: Fifty-three biopsy specimens from 13 patients at different times and sites were selected for this study. Microdissection was used to ensure the purity of tumor cells. DNA extraction, PCR, and direct sequencing of exons 5 through 8 of the TP53 gene were conducted following protocols optimized in our laboratory.

Results: We found that specimens from seven patients carried tumor-specific TP53 mutations. The number of lesions in these patients ranged from two to seven, extending from 2 to 4 years. All of the seven patients displayed identical mutations in the different microdissected tumors.

Conclusions: On the basis of these data, it appears that the recurrent bladder tumors originate from the same clone.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
L. E. Moore, A. H. Smith, C. Eng, S. DeVries, D. Kalman, V. Bhargava, K. Chew, C. Ferreccio, O. A. Rey, C. Hopenhayn, et al.
P53 alterations in bladder tumors from arsenic and tobacco exposed patients
Carcinogenesis, November 1, 2003; 24(11): 1785 - 1791.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.